ArticleFrontiers in immunology2025
Research landscape of glioma and inflammation over the past two decades.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cannabidiol- and Celecoxib-Loaded Liposomes as a Strategy to Modulate Redox and Inflammatory Signaling in High-Grade Glioma: A Preliminary In Vivo Study.International journal of molecular sciences · 2026Article
- Article
- Towards a personalized perspective on gliomas: an epigenetic-immuno-inflammatory aging framework.Frontiers in immunology · 2026Review
- Uncovering the Independent Role of Lipid Peroxidation in Osteoporosis Through an Integrated Bibliometric and Bioinformatics Analysis.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glioma is one of the most aggressive brain tumors, and its interaction with inflammation has become an emerging research focus. Despite increasing interest in the role of inflammation in glioma progression and therapy, a comprehensive bibliometric analysis of this field is lacking. Methods: We conducted a systematic bibliometric analysis of glioma and inflammation research using the Web of Science Core Collection (WoSCC). A total of 4,553 publications from 2005 to 2025 were analyzed for research trends, hotspots, key contributors, and emerging directions using CiteSpace and VOSviewer. Results: Our analysis revealed a significant increase in publications over the past decade. From 2005 to 2025, a total of 4,553 papers related to glioma and inflammation were published. Key contributing countries, institutions, and authors were identified, highlighting the dominance of the U.S. and China in this field. Leading institutions include MD Anderson Cancer Center and Harvard Medical School (USA) and several top Chinese universities. Keyword clustering and co-citation analysis indicated that expression, growth, and survival are major research hotspots. Highly cited papers primarily focused on molecular subtypes, immune modulation, and therapeutic resistance in glioma. ssGSEA analysis revealed that the score based on the 25-gene signature was significantly enriched in GBM and was closely associated with poor prognosis in GBM patients. Conclusion: Glioma and inflammation research have gained increasing attention, particularly in tumor immunity and microenvironment studies. This study outlines the current research landscape and trends, potentially serving as a reference for exploring future areas of investigation and collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.